You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 9,624,295

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,624,295

Title:	Uses and compositions for treatment of psoriatic arthritis
Abstract:	The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF.alpha. inhibitor, such as a human TNF.alpha. antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF.alpha. inhibitor for treatment of psoriatic arthritis in a subject.
Inventor(s):	Medich; John R. (East Hanover, NJ), Wong; Robert L. (Basking Ridge, NJ), Perdok; Renee J. (Gurnee, IL), Sasso; Eric H. (Evanston, IL), Hoffman; Rebecca S. (Wilmette, IL), Mease; Phillip (Seattle, WA), Ritchlin; Christopher T. (Canandaigua, NY)
Assignee:	Abbvie Biotechnology Ltd. (Hamilton, BM)
Application Number:	11/786,459
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,624,295
Patent Claims:	1. A method of treating a subject having oligoarthritis with a tender joint count (TJC)<5 or a swollen joint count (SJC)<5, in association with psoriatic arthritis, the method comprising administering to the subject about 40 mg of adalimumab once subcutaneously every other week, wherein at least an ACR20 response is achieved following a treatment period of at least about 12 weeks and the at least an ACR20 response is maintained following a treatment period of at least about 48 weeks, thereby treating the subject having psoriatic arthritis with oligoarthritis in association with psoriatic arthritis. 2. The method of claim 1, wherein at least an ACR50 response achieved by the subject following a treatment period of about 12 weeks and the at least an ACR50 response is maintained following a treatment period of at least about 48 weeks. 3. The method of claim 1, wherein said treatment period is about 48 weeks. 4. The method of claim 2, wherein said treatment period is about 48 weeks. 5. The method of claim 1, wherein at least an ACR70 response is achieved by the subject following a treatment period of about 12 weeks and the at least an ACR 70 response is maintained following a treatment period of at least about 48 weeks. 6. The method of claim 5, wherein said treatment period is about 48 weeks.

Details for Patent 9,624,295

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2026-04-10
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2026-04-10
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2026-04-10
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2026-04-10
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2026-04-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.